Novo Nordisk to build new corporate centre in Bagsværd, Denmark

Novo NordiskNovo Nordisk is investing around 1 billion Danish kroner (134 million euros) in two new office buildings with surrounding green space in Bagsværd, Denmark. The project is expected to create more than 300 jobs during the construction phase. The new office premises will house Novo Nordisk's top management, 1,100 administrative employees and a number of shared facilities. Groundbreaking will take place in October, and the new corporate centre is expected to be ready for occupancy at the end of 2013.

With the new premises, Novo Nordisk will be consolidating a number of administrative functions currently scattered across Greater Copenhagen. In future, the employees will be gathered at new, contemporary offices at the Bagsværd and Søborg sites.

"Although Novo Nordisk is primarily set to grow outside of Denmark in the coming years, we are looking forward to consolidating the administrative functions in Bagsværd, where we have been present since the 1950s. The new buildings will give our employees the best conditions for interacting across functional divides and with our colleagues abroad," says Lars Rebien Sørensen, president and CEO of Novo Nordisk.

The insulin molecule with its contoured spiral shape was a key source of inspiration for Henning Larsen Architects. The new building will be distinctive in its white materials combined with Nordic stone and woods. The aim is to create a dynamic and inspiring work setting closely allied with external natural features, in an elegant, streamlined and efficient centre for Novo Nordisk.

Around 14,000 of Novo Nordisk's 32,000 employees work in Denmark. Beyond the Copenhagen area, Novo Nordisk has activities in Kalundborg, Hillerød, Værløse, Måløv and Hjørring.

About the building project

  • The new corporate centre will consist of two office buildings - a circular, six-storey building and a lower, four-storey building, underground parking and a large planted landscape.
  • Situated on a 37,000 m2 site, the new buildings will take up an area of 8,800 m2 with a total floorage of 50,500 m2.
  • The buildings will feature low energy consumption with the aid of sensors, light and ventilation, and will meet the 2015 energy requirements for new buildings.

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

FDA approves first oral GLP-1 treatment for type 2…

The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along w...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...